Accelovance is committed to ensuring a smooth journey in the development of your compound. The Accelovance team works tirelessly as an extension of your team to optimize the timeline, conduct, budget, and quality of your clinical trial to maximize success.
You require a partner that will reliably deliver and assist you in navigating the complexity of oncology clinical trial development and execution. Early Phase Oncology (Phase I-II) is where Accelovance excels and differentiates itself from other CROs. We have optimized our oncology service offering by dedicating staff, technology, and assets to provide you with reliable and transparent access to data to facilitate decision making, robust team member experience to ensure exceptional execution in all development operations, and flexible solutions to meet your specific needs.
In addition, our unique Early Phase Oncology (EPO) offering leverages our staff, technology, site relationships and processes to improve the efficiency in conduct and reduce the cost of your critically important trials.
Accelovance Early Phase Oncology (EPO) Key Features & Benefits:
At Accelovance, we are accelerating oncology drug development. To learn how we can assist you in advancing your oncology pipeline, contact our team for more information by completing the form in the sidebar.
Expertise with the specific oncologic indication is also critically important when selecting the right partner for clinical trial conduct. To learn more about Accelovance's Oncology experience, click here to visit our Oncology Experience page.
Dr. Harish Dave, board certified oncologist, has been involved in over 100 clinical trials. He leads our Medical Affairs & Drug Safety group where he leverages over 25 years' experience gained from academia, as a principal investigator, and industry professional. Dr. Dave provides input and development within our Oncology consulting team along with Jamie Oliver, Chief Scientific Officer.